News - Pfizer, Gastro-intestinals

Filter

Current filters:

PfizerGastro-intestinals

Popular Filters

Pfizer in $2.15 billion settlement from Teva and Sun for infringement of Protonix patent

12-06-2013

Global pharma behemoth Pfizer (NYSE: PFE) today (June 12) said it has reached a $2.15 billion settlement…

Gastro-intestinalsGenericsLegalNorth AmericaPatentsPfizerPharmaceuticalProtonixSun Pharmaceutical IndustriesTeva Pharmaceutical Industries

Rhythm expands Series B financing to $33 Million, adding Pfizer Ventures as an investor

27-11-2012

Boston, USA-based biotech firm Rhythm Pharmaceuticals says it has raised an additional $8 million to…

BiotechnologyFinancialGastro-intestinalsIpsenPfizerResearchRhythm PharmaceuticalsRM-131

Pfizer links with SFJ Pharma for dacomitinib trial; settles with Mylan

10-09-2012

SFJ Pharmaceuticals Group, a global drug development group of companies which provides a unique co-development…

dacomitinibDetrol LAGastro-intestinalsGenericsLegalMylan LaboratoriesNorth AmericaOncologyPatentsPfizerPharmaceuticalResearchSFJ Pharmaceuticals

Pfizer RA drug candidate tofacitinib shows promise in ulcerative colitis

16-08-2012

Patients with moderately to severely active ulcerative colitis treated with drug behemoth Pfizer's (NYSE…

Gastro-intestinalsPfizerPharmaceuticalResearchtofacitinib

AstraZeneca to get $250 million-plus from OTC Nexium deal with Pfizer

15-08-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) says it has entered into an agreement with Pfizer (NYSE:…

AstraZenecaFinancialGastro-intestinalsGlobalLicensingNexiumPfizerPharmaceutical

AB Science leaps as GIST candidate masitinib beats Sutent

06-02-2012

France-based AB Science (AB: EN Paris) saw its share price rocket as much as 72% to 10.60 euros after…

AB ScienceGastro-intestinalsmasitinibOncologyPfizerPharmaceuticalResearchSutent

Back to top